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The purpose of this study was to evaluate the eﬀectiveness of intravitreal ranibizumab (Lucentis, Genentech, South San Francisco,
Calif, USA) combined with cataract surgery for the prevention of clinically signiﬁcant macular edema (CSME) in patients with
diabetic retinopathy (DR). This prospective interventional case series included ﬁfty-four eyes of 54 patients with a previous
diagnosis of nonproliferative diabetic retinopathy (NPDR) without macular edema preoperatively. Subjects were assigned in a
1:1 ratio to receive an intraoperative intravitreal ranibizumab injection (n = 27) or not (control group, n = 27) associated with
standardised phacoemulsiﬁcation surgery. The main outcome measure was the incidence of CSME one and three months after
surgery. One month after surgery the incidence of CSME in the control group was 25.92% and 3.70% in the treatment group and
at three months was 22.22% and 3.70%, respectively. Short-term results suggest that intravitreal ranibizumab immediately after
phacoemulsiﬁcation prevents CS ME in patients with NPDR.
1.Introduction
Diabetic macular edema (DME) is a major cause of central
visuallossindiabeticpatients[1].Ithasbeenwellestablished
bymanyauthorsthatDMEaftercataractsurgerycandiﬃcult
visual improvement [2, 3].
Shah and Chen [4] suggested that there is no clear evi-
dence that phacoemulsiﬁcation surgery causes progression
DME, particularly in patients with low-risk or absent dia-
betic retinopathy or in those with controlled retinal disease.
However, Kim et al. [5] suggested that 22% of diabetic
patients develop increases >30% in central retinal thickness
measured by optical coherence tomography (OCT) after
uncomplicated phacoemulsiﬁcation.
Many studies proposed the used of intravitreal bevacizu-
maborintravitrealsteroidsafterphacoemulsiﬁcationinpati-
ents with DME to prevent the increase in retinal thickening
and to improve the DME and ﬁnal visual acuity [6–8].
In this study, we injected Ranibizumab, eﬀective in the
treatment of wet macular degeneration and macular edema
[9–12], immediately after phacoemulsiﬁcation in diabetic
patients with some degree of diabetic retinopathy without
macular involvement and studied the macular thickness and
morphology by OCT 1 and 3 months after surgery.
2.MaterialandMethods
This prospective, randomized, and controlled intervention
study included a total of 54 eyes in 54 patients with cataract
and some degree of diabetic retinopathy. All patients were
enrolled from December 2009 to September 2010 and were
followed up for 3 months. The study protocol was approved
by the Ethics Committees of the centre. In addition, this
study has been performed in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki for
research involving human subjects.2 Journal of Ophthalmology
Patients were given an information sheet with the study
details, and signed speciﬁc informed consent forms for
inclusion in the study, cataract surgery and intravitreal
injection respectively.
Inclusion criteria were aged over 18 years and able to
make decisions, reduced visual acuity secondary to lens
sclerosis and some degree of diabetic retinopathy with-
out macular involvement. Exclusion criteria were previous
DME treated or not, any kind of complication during the
surgery, other ocular pathology with macular involvement
uncontrolled hypertension, recent myocardial infarction,
and cerebral vascular accident.
Patients undergoing standard cataract surgery (phacoe-
mulsiﬁcation with the Inﬁniti Vision System and monofocal
intraocular lens (IOL) implantation) were consecutively
assigned in a 1:1 ratio to receive an intravitreal injection
of ranibizumab (0.5mL of solution at 10mg/mL) at the
end of surgery or not (control group). All surgeries and
intravitreal injections were performed by the same surgeon
at the Department of Ophthalmology, University Hospital
La Fe in Valencia. Postoperative treatment was identical for
all the patients and consisted of the topical administration
of tobramycin-dexamethasone eye drops four times a day for
one month.
2.1. Clinical Examination. A complete ophthalmologic
examination was performed before, 1 and 3 months after
cataract surgery by the same observer in all cases. The
examination included slit lamp examination of the anterior
and posterior segment, visual acuity with and without
correction, goldmann tonometry, and measurement of the
central foveal thickness by OCT retinal examination. Brieﬂy,
all eyes underwent macular cube (512 × 128) scans with the
Cirrus HD-OCT system (Carl Zeiss Meditec, Dublin, Calif,
USA). The central subﬁeld thickness was calculated from the
mean of three consecutive measurements. The data obtained
in the control and Ranibizumab groups before, 1 and 3
months after surgery, were expressed as the mean ± S.D.,
and compared using the z-test.
The main outcome measured was the presence of clini-
cally signiﬁcant macular edema (CSME) deﬁned as macular
edema involving or threatening the centre of the macula as
deﬁned by the Early Treatment Diabetic Retinopathy Study
[13].
3. Results
A total of 54 eyes of 54 consecutive patients with no DME
measured by OCT were enrolled in the study in a ratio
1:1, 27 eyes in each group. All patients completed the study
at 1 and 3 months after surgery. Thirty-ﬁve women and
19 men were included, being equivalent the proportion of
patients of either sex included in both groups. The mean
patient age was also similar in the control and Ranibizumab
groups (68.9 ± 4.7 years versus 72.8 ± 5.2 years, resp.). All
the patients had a mild to moderate nonproliferative diabetic
retinopathy without any diﬀerences between control and
Ranibizumab groups. The clinical characteristics of patients
with diabetes are summarized in Table 1.
Table 1: Clinical characteristics of patients before the cataract
surgery.
Control group Ranibizumab group
Total eyes 27 27
Female 17 18
Male 10 9
Age 68.9 ±4.77 2 .8 ±5.2
Duration of diabetes (years) 13.4 ±6.41 4 .8 ±6.5
(a)
(b)
329
(c)
Figure 1: (a) fundus image corresponding to a patient enrolled
in the control group that did not receive the prophylaxis after the
cataract surgery (b), (c): OCT images of this patient showing the
important increase of macular thickness after the cataract surgery
without any prophilaxis.
3.1. Central Macular Thickness (Table 2). The mean central
thickness at baseline was 202µm in the control group
and 206µm in the Ranibizumab group, being no statically
signiﬁcant.
Seven eyes (25.92%) in the control group presented a
CSME measured by OCT compared to 1 in the RanibizumabJournal of Ophthalmology 3
Table 2: Central-macular thickness at baseline compare to 1 and 3 months after the cataract surgery in both groups (including only patients
that developed clinical signiﬁcant macular edema (∗CSME).
Control group Ranibizumab group
Patients CSME∗ at 1 month (%) 7 (25.92%) 1 (3.7%)
Patients CSME at 3 months (%) 6 (22.22%) 1 (3.7%)
CMT∗∗ Baseline (µm) 201.72 ±7.2 198
CMT at 1 month (µm) 315.7 ±36.8 312
CMT at 3 months (µm) 298.4 ±39.14 263
∗∗CMT: central macular thickness in patients with macular edema. Not included measurements of all eyes.
group (3.70%) the ﬁrst month after the surgery. At month
3, 1 patient experienced an improvement in the macular
thickness in the control group, so the ﬁnal percentage of
patientsthatdevelopedaCSMEaftercataractsurgerywas22.
22% in the control group (6 patients) compares to 3. 7% (1
patient) in the Ranibizumab group after 3 months of follow
up.
The mean central macular thickness increased from
201 ± 7.2µm before the surgery to 315,7 ± 36,8µma t
1 month and 298.4 ± 39.14µm at 3 months considering
the 7 patients that developed macular edema in the control
group (Figure 1). It is a mean increase of 105µmc o m p a r e d
to baseline in the patients that developed macular edema.
The eye in the Ranibizumab group with CSME after
phacoemulsiﬁcation (baseline macular thickness of 198µm)
improved its central thickness from 312µm1m o n t ha f t e r
the surgery to 263µm at month 3, but it was still clinically
signiﬁcant (Final total increase of 65µm at the end of the
follow up).
No local or systemic adverse eﬀects were observed in the
Ranibizumab group.
4. Discussion
This study is, to our knowledge, the ﬁrst one to report the
eﬀectiveness of Ranibizumab in the prevention of CSME
after phacoemulsiﬁcation in patients with mild to moderate
diabetic retinopathy.
It has been reported that the VEGF, induced by ocular
hypoxia, is an important factor in the development of abnor-
mal angiogenesis and macular edema [14]. Ranibizumab,
a recombinant, humanized, monoclonal antibody Fab that
neutralizes all active forms of VEGF-A, has recently demon-
strated its eﬀectiveness for the treatment of diabetic macular
edema [15]. Previously, some reports conﬁrmed the use-
fulness of Bevacizumab, a humanized monoclonal antibody
that inhibits all isoforms of VEGF, in the prevention of
macular thickening after phacoemulsiﬁcation [6, 7, 16].
Bevacizumabisamoleculedesignedtotreatthecoloncancer,
and Ranibizumab has been specially designed to treat ocular
pathology, so the use of Bevacizumab in ocular pathology
can be controversial. The success with Bevacizumab in
previous studies together with this oﬀ-label use of the drug
in ophthalmology prompted us to investigate whether the
prophylactic use of Ranibizumab in diabetic patients could
prevent the development of CSME.
In our results, 25.92% of the eyes in the control group
develop a macular thickening which results in a CSME at
1 and 3 months postoperatively. These results are slightly
higher to that found by Kim et al. [5], who concluded
that 22% of diabetic patients developed increases of the
center point thickness of >30% 4 weeks after uncomplicated
phacoemulsiﬁcation. The main diﬀerence between both
studies is that only patients with mild to moderate diabetic
retinopathy were included in our study, and Kim et al. also
included patients with none diabetic retinopathy.
The mean central thickness increased in 105µmi n
the 7 eyes of the control group. This value is similar to
that published by many series in diabetic patients after
phacoemulsiﬁcation [6, 16, 17]. In the treatment group only
1 patient develop a CSME with an increase in the central
thickness of 65µm, being statically signiﬁcant the diﬀerences
between both groups.
Limitations of our study include the short duration of
followup, which precludes the determination of the long
term safety and eﬃcacy of prophylactic Ranibizumab in
cataract surgery and the number of patients included in the
study. However, CME develops shortly after cataract surgery
with a maximum at 4–6 weeks postop [18]. Our study
determined the incidence of CSME at 1 and 3 months, and
there was no evidence that new cases of macular edema had
developed in the following months if we consider that there
were no new cases appearing between the ﬁrst and the third
month after the cataract surgery.
Although further investigation with a longer followup
and a larger series of patients may be needed, the intravitreal
injection of Ranibizumab immediately after the phacoemul-
siﬁcation and intraocular lens implantation may be a potent
tool to prevent clinical signiﬁcant macular edema after
cataract surgery according to our results.
5. Conclusions
In summary, the combination of intravitreal Ranibizumab
and uncomplicated phacoemulsiﬁcation avoids the macular
thickening measured by OCT in mild to moderate diabetic
retinopathy patients without previous macular involvement.
Although the small number of patients and the short4 Journal of Ophthalmology
followup,theresultsseemtobepromisingwithnoincreasing
risk for the patient.
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